Register Now: Tribe Public’s 30-Minute Deep Dive on Making EoE a Once‑a‑Year Appointment -( $EPRX $SNY $IBB $XBI )

Vista Partners is passing along a timely heads-up from our sister organization, Tribe Public www.TribePublic.com, which is convening a compact but information‑dense CEO Presentation & Q&A Webinar event tomorrow, Wednesday, April 1 at 8:00am PT / 11:00am ET, titled “Turning EOE Into a Once-a-Year Appointment.” In a market where investor calendars resemble over-subscribed roadshows, a 30‑minute session that actually ends on time already qualifies as innovation.

The event will feature James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who will discuss the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. The format is designed for investors, advisors, and healthcare professionals who prefer direct access to management over reading yet another 40‑page deck at midnight.

Reserve Your Seat Now:

Vista Partners encourages clients and readers tracking innovation in EoE, osteoarthritis pain, and locally delivered, extended‑release therapeutics to register and listen in. To reserve a seat, please visit Treat-EOE-Once-a-Year.TribePublic.com and complete the short registration process. Questions for Dr. Helliwell can be submitted in advance via research@tribepublic.com or asked live in the Zoom chat. Sharing the link with a colleague who enjoys early looks at emerging biotech stories is not only permitted, it is quietly encouraged.

Below is a high‑level snapshot of Eupraxia’s reported progress over roughly the last six months:

• Reported advancement of its long‑acting corticosteroid candidate for osteoarthritis pain into or through key Phase 2 milestones, with management reiterating its focus on durability of effect and localized delivery.
• Provided an update on its EoE program, positioning its extended‑release technology as a potential “once‑a‑year” intervention in an indication where treatment burden remains non‑trivial.
• Highlighted additional applications of its Diffusphere™ micro‑sphere platform in other high‑unmet‑need indications, underscoring a broader pipeline rather than a one‑asset narrative.
• Communicated on balance sheet and funding runway through the end of 2028, outlining resources intended to support clinical and corporate objectives into upcoming value‑inflection events.
• Participated in investor conferences and non‑deal roadshows, increasing visibility with institutional investors, strategic stakeholders and the sell side.
• Wall Street Analysts currently have one year price targets that range from $11 to as high as $19/share.

Vista Partners looks forward to joining the discussion and will be monitoring how the story evolves from here—ideally with fewer injections, more durability, and a treatment schedule that even a busy portfolio manager could keep.

Learn More

Yes indeed, Eupraxia Pharmaceutical’s (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time. Eosinophilic esophagitis (EoE) has matured from “zebra” to mainstream GI diagnosis, with roughly 500,000 known U.S. cases and credible arguments that the real number is closer to one million. Emergency room data showing hundreds of thousands of young men with classic symptoms but no code in the chart suggest the epidemiology is still catching up to reality. As awareness grows, experts expect the pool of diagnosed patients to double or even triple over the next 5–10 years, turning EoE from niche to necessary line item on every GI group’s strategic plan. For now, diagnosis still requires endoscopy with biopsy—there is no non-endoscopic shortcut—cementing the procedure suite as both the diagnostic and, increasingly, therapeutic center of gravity. Read more.

The Sources

1. Company website (overview, pipeline, Diffusphere™): https://eupraxiapharma.com[1]
2. Overview of EP‑104IAR clinical trial in knee osteoarthritis (SPRINGBOARD): https://clinicaltrials.gov/study/NCT04120402[2]
3. Lancet Rheumatology publication of EP‑104IAR Phase 2b knee osteoarthritis data (press release): https://www.prnewswire.com/news-releases/lancet-rheumatology-publishes-phase-2b-data-on-eupraxia-pharmaceuticals-ep-104iar-for-the-treatment-of-knee-osteoarthritis-301958027.html[3]
4. Corporate/clinical update across EP‑104IAR and EP‑104GI programs: https://www.linkedin.com/pulse/eupraxia-pharmaceuticals-announces-clinical-1omfc[4]
5. Six‑month symptom data and broader program commentary: https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-six-month-110000698.html[5]
6. RESOLVE Phase 1b/2a trial description for EP‑104GI in EoE (ClinicalTrials.gov): https://clinicaltrials.gov/study/NCT05608681[6]
7. Article on positive RESOLVE EoE https://www.clinicaltrialsarena.com/news/eupraxia-eosinophilic-esophagitis-trial/[7]
8. Press release on additional positive data from RESOLVE Phase 1b/2a trial: https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-announces-positive-data-from-resolve-phase-1b2a-trial-of-ep-104gi-in-patients-with-eosinophilic-esophagitis-302381992.html[8]
9. Diffusphere™ targeted, extended‑release PK data in OA and EoE: https://www.prnewswire.com/news-releases/eupraxias-diffusphere-technology-demonstrates-targeted-drug-release-while-minimizing-systemic-exposure-for-a-period-of-more-than-six-months-302090889.html[9]
10. Recent financing / balance sheet update and Diffusphere™ description: https://firstwordpharma.com/story/7110925[10]